04/17/2026
🧠A new Cochrane review of 17 clinical trials involving more than 20,000 people has found that anti-amyloid drugs likely show no clinically meaningful benefit.
People with Alzheimer’s disease have high levels of a protein known as amyloid beta in their brains, detectable before symptoms begin, but its role in disease progression is uncertain. Drugs have been developed to remove these proteins from the brain, under the theory that this would prevent or slow disease progression.
Early trials showed statistically significant results, but these did not translate into a meaningful difference for patients' cognition or daily life. On top of that, the drugs were linked to an increased risk of brain swelling and bleeding.
🧑‍🔬 The researchers are now calling for future Alzheimer's research to focus on completely different pathways.
Senior author, Edo Richard, Professor of Neurology at Radboud University Medical Centre, explained that he sees Alzheimer’s patients in his clinic every week and he wishes he had an effective treatment to offer them
💬 “Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments. Sadly, anti-amyloid drugs do not offer this and bring additional risks. Given the absence of correlation between amyloid removal and clinical benefit, we need to explore other pathways to help address this devastating disease.”
IRCCS Istituto delle Scienze Neurologiche di Bologna Radboudumc
đź”— Read more: https://www.cochrane.org/about-us/news/anti-amyloid-alzheimers-drugs-show-no-clinically-meaningful-effect
